Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition.
Wilkinson S, Ku AT, Lis RT, King IM, Low D, Trostel SY, Bright JR, Terrigino NT, Baj A, Fenimore JM, Li C, Vo B, Jansen CS, Ye H, Whitlock NC, Harmon SA, Carrabba NV, Atway R, Lake R, Kissick HT, Pinto PA, Choyke PL, Turkbey B, Dahut WL, Karzai F, Sowalsky AG.
Wilkinson S, et al. Among authors: dahut wl.
medRxiv [Preprint]. 2024 Feb 11:2024.02.09.24302395. doi: 10.1101/2024.02.09.24302395.
medRxiv. 2024.
PMID: 38370835
Free PMC article.
Preprint.